DDW News

Speaker Spotlight: Scott L. Friedman, MD

Scott L. Friedman, MD

Scott L. Friedman, MD
Scott L. Friedman, MD

Dean, Therapeutic Discovery and Chief of Liver Diseases, Icahn School of Medicine, Mount Sinai
Twitter: @scottfriedmanmd

Session:

Anti-Fibrotics: Do We Need More Targets?

DDW Track:

Liver Diseases and Transplantation

Date and Time:

Friday, May 21, 3:30–5 p.m.

CME:

1.5 hours

Session Description

Dramatic advances in elucidating the pathogenesis of hepatic fibrosis have led to emerging therapies for patients with chronic liver disease. This state-of-the-art lecture will introduce established and new principles of fibrosis pathogenesis in liver. The persistent unmet need and current obstacles to antifibrotic therapies have led to new models and approaches that will refine and improve existing and new therapies.

After attending this session, participants will be able to:

  • Identify the cellular basis for fibrosis in chronic liver disease.
  • Understand how new targets are translated into new therapies.
  • Clarify the obstacles to effective antifibrotic therapies, especially in NASH.

This session is included in the cost of registration for DDW 2021 and will be available to watch live or on demand until Aug. 23, 2021. Discounted registration rates are available through March 31. View the DDW Online Planner for the full DDW agenda over May 21-23.

Dr. Friedman has performed pioneering research into the underlying causes of fibrosis associated with chronic liver diseases. His work has spawned an entire field that is now realizing its translational therapeutic potential. A mentor of over 85 fellows and students, he is widely respected as a key opinion leader working closely with the biotech and pharmaceutical industry in developing new therapies for liver disease. You can connect with Dr. Friedman via live chat during the session.

Leave a Reply

Your email address will not be published.